Brand Name Drug Negotiations Status

The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards, the Canadian Agency for Drugs and Technologies in Health (CADTH) which reviews common drugs through the Common Drug Review (CDR) and oncology drugs through the Pan-Canadian Oncology Drug Review (pCODR). In Quebec, drugs are reviewed through l’Institut national d’excellence en santé et en services sociaux (INESSS). For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by CADTH and/or INESSS.

Product Manufacturer Status Indication
Blood glucose test strips (blood glucose test strips) ForaCare Technology Canada, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Skymed Monitors Inc. Active Negotiation Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) MediSure Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) LifeScan Canada ULC Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) I-Sens, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) BTNX Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Ascensia Diabetes Care Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Spirit Healthcare Group Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Abbott Diabetes Care Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Retevmo (selpercatinib) Eli Lilly Canada Inc. Under consideration for negotiation indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients
Qinlock (ripretinib) Medison Pharma Canada Inc. Under consideration for negotiation For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib
Insulin pumps and pump supplies (insulin pumps and pump supplies) Insulet Canada Corporation Active Negotiation Diabetes Mellitus, Type 1 & 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Ypsomed Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Medtronic Canada Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Intrarosa (prasterone) Lupin Pharma Canada Ltd. Under consideration for negotiation postmenopausal vulvovaginal atrophy
Tavalisse (fostamatinib) Medison Pharma Canada Negotiations were not pursued chronic immune thrombocytopenia
Bimzelx (bimekizumab) UCB Canada Inc. Under consideration for negotiation psoriasis, moderate to severe plaque
Pemazyre (pemigatinib) Incyte Biosciences Canada Corporation Under consideration for negotiation adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement
Lorbrena (lorlatinib) Pfizer Canada ULC Under consideration for negotiation Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Adtralza (tralokinumab) LEO Pharma Inc. Negotiations were not pursued atopic dermatitis
Myinfla (colchicine) Pendopharm, a division of Pharmascience Inc. Negotiations were not pursued atherothrombotic events in coronary artery disease
Ngenla (somatrogon) PFIZER CANADA ULC. Under consideration for negotiation growth hormone deficiency
Libtayo (cemiplimab) Sanofi Genzyme Under consideration for negotiation For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Under consideration for negotiation Opdivo — in combination with fluoropyrimidine- and platinum-containing chemotherapy — for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients
Leqvio (inclisiran) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation Primary hypercholesterolemia (non-familial and heterozygous familial)
Ultomiris (ravulizumab) Alexion Pharma Canada Corp. Under consideration for negotiation Paroxysmal nocturnal hemoglobinuria (PNH)
Bijuva (estradiol and progesterone) Knight Therapeutics Inc. Under consideration for negotiation vasomotor symptoms associated with menopause
Waymade-Trientine (trientine hydrochloride) Waymade Canada Inc  Active Negotiation Wilson's Disease
Vectibix (panitumumab) Amgen Canada Inc. Active Negotiation For the treatment of metastatic colorectal cancer
Phesgo SC (perjeta and herceptin) HOFFMANN-LA ROCHE LIMITED Concluded without agreement For the first-line treatment of patients with HER2-positive metastatic breast cancer
Darzalex SC (Daratumumab) Janssen Inc. Concluded with an LOI Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
Trodelvy (sacituzumab govitecan) Gilead Sciences Canada Inc. Under consideration for negotiation For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease
Sarclisa (Isatuximab) Sanofi Genzyme Active Negotiation In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
Piqray (alpelisib) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Under consideration for negotiation For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)
Perjeta (pertuzumab) HOFFMANN-LA ROCHE LIMITED  Under consideration for negotiation In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive)
Increlex (mecasermin) Ipsen Biopharmaceuticals Canada, Inc. Under consideration for negotiation insulin-like growth factor-1 deficiency
Dojolvi (triheptanoin) Ultragenyx Canada Inc. Active Negotiation long-chain fatty acid oxidation disorders
Trazimera (trastuzumab) Pfizer Canada ULC Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Herzuma (trastuzumab) Teva Canada Limited Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Ogivri (trastuzumab) BGP Pharma ULC Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kanjinti (trastuzumab) Amgen Canada Inc. Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Imvexxy (estradiol) Knight Therapeutics Inc. Under consideration for negotiation postmenopausal dyspareunia
Tagrisso (osimertinib) AstraZeneca Canada Inc. Active Negotiation Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Opdivo-Yervoy (nivolumab-ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Kyprolis (carfilzomib) Amgen Canada Inc. Concluded with an LOI Treatment of multiple myeloma (including relapsed)
Padcev (enfortumab vedotin) Seagen Canada Inc. Under consideration for negotiation Treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy
Ontruzant (trastuzumab) Organon Canada Inc. Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Mvasi (bevacizumab) Amgen Canada Inc. Concluded with an LOI first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen
Opsynvi (macitentan and tadalafil) Janssen Inc. Concluded without agreement pulmonary arterial hypertension
Emgality (galcanezumab) Eli Lilly Canada Inc. Active Negotiation Prevention of migraine
Reblozyl (luspatercept) Celgene Inc. Active Negotiation transfusion dependent anemia associated with MDS
Brukinsa (zanubrutinib) BeiGene, Ltd. Under consideration for negotiation Waldenström’s macroglobulinemia
Ledaga (chlormethine hydrochloride) Recordati Rare Diseases Canada Inc. Under consideration for negotiation For the topical treatment of stage IA and IB mycosis fungoidestype cutaneous Tcell Lymphoma (MF-CTCL) in adult patients who have received prior skindirected therapy
Evenity (romosozumab) Amgen Canada Inc. Active Negotiation osteoporosis
MAR-Trientine (trientine) Marcan Pharmaceuticals Inc. Concluded with an LOI Wilson's Disease
Tukysa ( tucatinib) Seagen Canada Inc. Active Negotiation Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination
Abecma (idecabtagene vicleucel) Celgene Inc. Under consideration for negotiation For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Zaxine (rifaximin) Lupin Pharma Canada Limited Active Negotiation Hepatic Encephalopathy
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Aybintio (bevacizumab) Organon Canada Inc. Concluded with an LOI For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) – Glioblastoma
Onureg (azacitidine) Celgene Inc. Active Negotiation Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Abrilada (adalimumab) Pfizer Canada ULC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Yuflyma (adalimumab) Celltrion Healthcare Canada Ltd. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Kirsty (insulin aspart) Viatris Canada Active Negotiation Diabetes Mellitus, Type 1 & 2
Givlaari (givosiran) Alnylam Netherlands B.V. Active Negotiation acute hepatic porphyria
Xeomin (incobotulinumtoxinA) Merz Therapeutics Canada Active Negotiation chronic sialorrhea associated with neurological disorders
Perseris (risperidone) HLS Therapeutics Inc. Active Negotiation Schizophrenia
Inqovi (Decitabine-Cedazuridine) Taiho Pharma Canada, Inc. Concluded without agreement Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Saxenda (liraglutide) Novo Nordisk Canada Inc. Negotiations were not pursued chronic weight management
Vitrakvi (larotrectinib) Bayer Inc. Active Negotiation For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate) ASTRAZENECA CANADA INC Active Negotiation Chronic Obstructive Pulmonary Disease
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic Fibrosis, F508del CFTR mutation
Vyxeos (daunorubicin and cytarabine) Jazz Pharmaceuticals Canada Inc. Concluded with an LOI For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Tecartus (brexucabtagene autoleucel) Gilead Sciences Canada Inc. Active Negotiation For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Evrysdi (risdiplam) HOFFMANN-LA ROCHE LIMITED  Concluded with an LOI Spinal Muscular Atrophy
Rinvoq (upadacitinib) AbbVie Corporation Active Negotiation Psoriatic Arthritis
Entuzity KwikPen (human insulin) Eli Lilly Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Jorveza (budesonide) AVIR Pharma Inc. Active Negotiation eosinophic esophagitis (maintenance)
Venclexta (venetoclax) AbbVie Corporation Negotiations were not pursued Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Venclexta (venetoclax) AbbVie Corporation Concluded with an LOI in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Entresto (sacubitril/valsartan) Novartis Pharmaceuticals Canada Inc. Active Negotiation Heart failure, NYHA class II or III
Opdivo-Yervoy (nivolumab-ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Imfinzi (durvalumab) AstraZeneca Canada Inc. Concluded with an LOI IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Braftovi (encorafenib) PFIZER CANADA ULC. Active Negotiation Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy,
Braftovi/Mektovi (encorfenib/binimetinib) PFIZER CANADA ULC Active Negotiation Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test
Unituxin (dinutuximab) United Therapeutics Concluded with an LOI high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor
Inrebic (fedrantinib) Celgene Inc. Concluded with an LOI Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib
Zeposia (ozanimod) Celgene Inc. Negotiations were not pursued Relapsing-Remitting Multiple Sclerosis
Rybelsus (semaglutide) Novo Nordisk Canada Inc. Active Negotiation Diabetes Mellitus, Type 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Tandem Diabetes Care Canada, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Veltassa (patiromer) Otsuka Canada Pharmaceuticals Inc. Concluded without agreement hyperkalemia
Reblozyl (luspatercept) Celgene Inc. Active Negotiation anemia associated with beta-thalassemia
Dupixent (dupilumab) Sanofi Genzyme Active Negotiation Asthma
Tafinlar/Mekinist (dabrafenib/trametinib) Novartis Pharmaceuticals Canada Inc. Active Negotiation Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease
Ilumya (tildrakizumab) Sun Pharma Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Simlandi (adalimumab) Jamp Pharma Corporation Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Corzyna (ranolazine) KYE Pharmaceuticals Under consideration for negotiation Angina pectoris
Zejula (Niraparib) GlaxoSmithKline Inc. Concluded with an LOI Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
Odomzo (sonidegib) Sun Pharma Canada Inc. Negotiations were not pursued Basal Cell Carcinoma (BCC): For the treatment of adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery
Bambevi (bevacizumab) Apotex Inc. Concluded with an LOI Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma
Polivy (Polatuzumab Vedotin) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy.
Alunbrig (brigatinib) Takeda Canada Inc. Concluded with an LOI For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA
Rozlytrek (Entrectinib) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI ROS1-positive Non-Small Cell Lung Cancer
Ruzurgi (Amifampridine) Médunik Canada Inc. Active Negotiation Lambert-Eaton myasthenic syndrome (LEMS)
Enspryng (satralizumab) HOFFMANN-LA ROCHE LTD Active Negotiation neuromyelitis optica spectrum disorders (NMOSD)
Osnuvo (teriparatide) AVIR Pharma Inc. Concluded with an LOI osteoporosis
Sarclisa (Isatuximab) Sanofi Genzyme Active Negotiation Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Remsima SC (infliximab) Celltrion Healthcare Canada Ltd. Concluded without agreement Rheumatoid Arthritis
Abevmy (bevacizumab) BGP Pharma ULC Concluded with an LOI Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Bavencio (avelumab) EMD Serono a Division of EMD Inc. Canada Concluded with an LOI Indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy
Ajovy (fremanezumab) Teva Canada Inc. Concluded with an LOI prevention of migraine in adults
Entresto (sacubitril/valsartan) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation Heart failure, NYHA class II or III
Calquence (Acalabrutinib) ASTRAZENECA CANADA INC Concluded with an LOI Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Calquence (Acalabrutinib) ASTRAZENECA CANADA INC Concluded with an LOI Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Kynmobi (apomorphine hydrochloride) Sunovion Pharmaceuticals Canada Inc. Concluded with an LOI Parkinson's Disease
Kesimpta (ofatumumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Relapsing-Remitting Multiple Sclerosis
Ofev (nintedanib) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Chronic fibrosing interstitial lung diseases
Darzalex SC (Daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma
Daurismo (Glasdegib) PFIZER CANADA ULC Negotiations were not pursued Acute Myeloid Leukemia (AML)
pdp-levETIRAcetam (levetiracetam) Pendopharm Active Negotiation Epilepsy
Zolgensma (onasemnogene abeparvovec) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Spinal Muscular Atrophy
Tecentriq and bevacizumab (Atezolizumab & Bevacizumab) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Head and Neck Squamous Cell Carcinoma (HNSCC)
Forxiga (dapagliflozin) AstraZeneca Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Entyvio (SC) (vedolizumab) Takeda Canada Inc. Concluded with an LOI Crohn's disease
Venclexta (venetoclax) AbbVie Corporation Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Hodgkin's Lymphoma
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)
Spravato (esketamine hydrochloride) JANSSEN INC Negotiations were not pursued Major Depressive Disorder
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Riabni (rituximab) Amgen Canada Inc. Concluded with an LOI Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Inclunox (enoxaparin) Sandoz Canada Inc. Concluded with an LOI Deep vein thrombosis (treatment and prevention)
Noromby (enoxaparin) Juno Pharmaceuticals Corp. Concluded with an LOI Deep vein thrombosis (treatment and prevention)
Nyvepria (pegfilgrastim) Pfizer Canada Inc. Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Trurapi (insulin aspart) SANOFI-AVENTIS Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Foquest (methylphenidate) Elvium Life Sciences Concluded with an LOI Attention-deficit/hyperactivity disorder (ADHD)
Suboxone (film) (buprenorphine and naloxone) Indivior UK Limited Concluded with an LOI Opioid drug dependence
Atectura Breezhaler (indacaterol /mometasone furoate) Valeo Pharma Inc. Concluded with an LOI Asthma
Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate) Valeo Pharma Inc. Concluded with an LOI Asthma
Luxturna (voretigene neparvovec) Novartis Pharmaceuticals Canada Inc. Active Negotiation Inherited retinal disease
Blood glucose test strips (blood glucose test strips) Multiple manufacturers Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Hadlima (adalimumab) Merck Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Idacio (adalimumab) Fresenius Kabi Canada Ltd. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Hyrimoz (adalimumab) Sandoz Canada Inc. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Amgevita (adalimumab) AMGEN CANADA INC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Hulio (adalimumab) BGP Pharma ULC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Jorveza (budesonide) AVIR Pharma Inc. Active Negotiation Eosinophilic esophagitis
Duobrii (Halobetasol propionate and tazarotene) Bausch Health, Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Nexplanon (etonogestrel) MERCK CANADA INC Concluded with an LOI prevention of pregnancy
Soliris (eculizumab) Alexion Pharma GMBH Active Negotiation Myasthenia Gravis
Zejula (Niraparib) GlaxoSmithKline Inc. Concluded with an LOI Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Xtandi (enzalutamide) Astellas Pharma Inc. Concluded with an LOI Metastatic Castration Sensitive Prostate Cancer
Cablivi (caplacizumab) SANOFI-AVENTIS Negotiations were not pursued acquired thrombotic thrombocytopenic purpura (aTTP)
Rituxan SC (rituximab) Hoffmann-La Roche Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Tecentriq & Avastin (Atezolizumab & Bevacizumab) HOFFMANN-LA ROCHE LIMITED Negotiations were not pursued Non-Squamous Non-Small Cell Lung Cancer
Aimovig (erenumab) NOVARTIS PHARMACEUTICALS CANADA INC Concluded without agreement migraine, chronic
Vocabria and Cabenuva (cabotegravir and rilpivirine) VIIV HEALTHCARE ULC Concluded with an LOI HIV Infection
Mayzent (siponimod) NOVARTIS PHARMACEUTICALS CANADA INC Concluded with an LOI Secondary progressive multiple sclerosis (SPMS)
Vascepa (icosapent ethyl) HLS Therapeutics Inc. Concluded with an LOI Ischemic events in statin-treated patients
Stelara (ustekinumab) Janssen Inc. Concluded without agreement Ulcerative Colitis
Soliris (eculizumab) Alexion Pharma GMBH Active Negotiation Neuromyelitis optica spectrum disorder (NMOSD)
Darzalex SC (Daratumumab) Janssen Inc. Concluded without agreement Multiple Myeloma
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Peripheral T-Cell Lymphoma
Cuvposa (Glycopyrrolate) Medexus Inc. Under consideration for negotiation chronic severe drooling, neurologic (pediatric)
Xospata (Gilteritinib) Astellas Pharma Inc. Concluded with an LOI Acute Myeloid Leukemia
Aermony Respiclick (fluticasone propionate) Teva Canada Limited Concluded with an LOI Asthma
Kisqali (ribociclib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Advanced or Metastatic Breast Cancer
Kalydeco (ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Orkambi (lumacaftor/ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic Fibrosis, F508del CFTR mutation
Contrave (naltrexone hydrochloride and bupropion hydrochloride) Bausch Health, Canada Inc. Negotiations were not pursued Chronic weight management
Nubeqa (Darolutamide) Bayer Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Erleada (apalutamide) Janssen Inc. Concluded with an LOI Metastatic Castration-Sensitive Prostate Cancer
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Concluded with an LOI For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Crysvita (burosumab) Ultragenyx Canada Inc. Concluded with an LOI X-Linked Hypophosphatemia
Entyvio (SC) (vedolizumab) Takeda Canada Inc. Concluded with an LOI Ulcerative Colitis
Dupixent (dupilumab) Sanofi Genzyme Concluded with an LOI Atopic dermatitis
Beovu (brolucizumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Age-Related Macular Degeneration
Benlysta (belimumab) GlaxoSmithKline Under consideration for negotiation Systemic lupus erythematosus
Kisqali (with fulvestrant) (ribociclib with fulvestrant) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Advanced or Metastatic Breast Cancer
Allerject (epinephrine) Kaleo Inc Concluded with an LOI For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Otezla (apremilast) Amgen Canada Inc. Concluded without agreement Psoriatic Arthritis
Otezla (apremilast) Amgen Canada Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Avsola (infliximab) Amgen Canada Inc. Concluded with an LOI Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis
Nivestym (filgrastim) Pfizer Canada ULC Concluded with an LOI Prevention or treatment of neutropenia in various indications
Ziextenzo (pegfilgrastim) Sandoz Canada Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Redesca (enoxaparin) Valeo Pharma Inc. Concluded with an LOI Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
Kanjinti (trastuzumab) Amgen Canada Inc. Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Envarsus PA (tacrolimus) Paladin Labs Inc. Concluded with an LOI prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients
Onstryv (safinamide) Valeo Pharma Inc. Under consideration for negotiation Parkinson's Disease
Monoferric (iron (iii) isomaltoside 1000) Pharmacosmos A/S Concluded with an LOI iron deficiency anemia
Lokelma (sodium zirconium cyclosilicate) AstraZeneca Canada Inc. Negotiations were not pursued hyperkalemia
Taltz (ixekizumab) Eli Lilly Canada Inc. Concluded without agreement Ankylosing spondylitis
Vyndaqel (tafamidis) Pfizer Canada ULC Concluded with an LOI transthyretin-mediated amyloidosis
Rinvoq (upadacitinib) AbbVie Corporation Active Negotiation Rheumatoid Arthritis
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Concluded with an LOI metastatic Gastric Cancer
Riximyo (rituximab) Sandoz Canada Concluded with an LOI Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
Ruxience (rituximab) Pfizer Canada ULC Concluded with an LOI Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Lutathera (lutetium 177 dotatate) Advanced Accelerator Applications Concluded with an LOI Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Baqsimi (glucagon) Eli Lilly Canada Inc. Concluded with an LOI severe hypoglycemia
Admelog (insulin lispro) Sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Lorbrena (lorlatinib) Pfizer Canada ULC Negotiations were not pursued Non-Small Cell Lung Cancer (ALK+)
Rydapt (midostaurin) Novartis Pharmaceuticals Canada Inc. Negotiations were not pursued Systemic Mastocytosis
Mylotarg (gemtuzumab ozogamicin) Pfizer Canada ULC Concluded with an LOI Acute Myeloid Leukemia
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI renal cell carcinoma
Nerlynx (neratinib) Knight Therapeutics Negotiations were not pursued Hormone Receptor-Positive Breast Cancer
Cimzia (certolizumab pegol) UCB Canada Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Takhzyro (lanadelumab) Shire Pharma Canada ULC Concluded with an LOI Hereditary Angioedema
Revestive (teduglutide) Shire Pharma Canada ULC Concluded with an LOI Short Bowel Syndrome (SBS)
Verkazia (cyclosporine) Santen Incorporated Concluded with an LOI severe vernal keratoconjunctivitis
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Negotiations were not pursued Metastatic Colorectal Cancer
Mezera (mesalazine) AVIR Pharma Inc. Concluded with an LOI Ulcerative Colitis
Kadcyla (trastuzumab emtansine) Hoffmann-La Roche Concluded with an LOI early breast cancer
Darzalex (daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Squamous Non-Small Cell Lung Cancer
Tecentriq (atezolizumab) Hoffmann-La Roche Concluded with an LOI For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Trintellix (vortioxetine) Lundbeck Canada Inc. Concluded with an LOI Major Depressive Disorder
Xultophy (insulin degludec/liraglutide) Novo Nordisk Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Dovato (dolutegravir/lamivudine) ViiV Healthcare Concluded with an LOI HIV Infection
Iluvien (fluocinolone acetonide) Knight Therapeutics Negotiations were not pursued Diabetic Macular Edema
Emerade (epinephrine bitartrate) Bausch Health, Canada Inc. Concluded with an LOI For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Bosulif (bosutinib) Pfizer Canada ULC Concluded with an LOI Chronic Myeloid Leukemia
Olumiant (baricitinib) Eli Lilly Canada Inc. Concluded with an LOI Rheumatoid Arthritis
Orfadin Oral Suspension (nitisinone) Sobi Canada Inc. Concluded without agreement Hereditary Tyrosinemia Type 1
Onpattro (patisiran) Alnylam Netherlands B.V. Concluded with an LOI hereditary transthyretin-mediated amyloidosis
Tegsedi (inotersen) Akcea Therapeutics Inc. Concluded with an LOI hereditary transthyretin-mediated amyloidosis
Truxima (rituximab) Teva Canada Limited Concluded with an LOI Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
Vitrakvi (larotrectinib) Bayer Inc. Negotiations were not pursued Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Pomalyst (pomalidomide) Celgene Inc. Negotiations were not pursued Multiple Myeloma (Relapsed)
Idhifa (enasidenib) Celgene Inc. Under consideration for negotiation Acute Myeloid Leukemia
Revlimid (lenalidomide) Celgene Inc. Concluded with an LOI Multiple Myeloma
Sublocade (buprenorphine) Indivior UK Limited Concluded with an LOI Opioid Use Disorder
Cystadrops (cysteamine) Recordati Canada Concluded with an LOI corneal cystine crystal deposits
Libtayo (cemiplimab) Sanofi Genzyme Concluded with an LOI Cutaneous Squamous Cell Carcinoma
Lenvima (lenvatinib) Eisai Limited Concluded with an LOI For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Darzalex (daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma (newly diagnosed)
Lutathera (lutetium 177 dotatate) Advanced Accelerator Applications Concluded without agreement Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Alunbrig (brigatinib) Takeda Canada Inc. Negotiations were not pursued Non-Squamous Non-Small Cell Lung Cancer
Ninlaro (ixazomib) Takeda Canada Inc. Negotiations were not pursued Multiple Myeloma
Verzenio (abemaciclib) Eli Lilly Canada Inc. Concluded without agreement Advanced or Metastatic Breast Cancer
Vizimpro (dacomitinib) Pfizer Canada ULC Concluded without agreement Non-Squamous Non-Small Cell Lung Cancer
Keytruda (pembrolizumab) Merck Canada Inc. Negotiations were not pursued Metastatic Urothelial Carcinoma (first line)
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Melanoma adjuvant therapy
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Non-Squamous Non-Small Cell Lung Cancer
Venclexta/rituximab (venetoclax/rituximab) AbbVie Corporation Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Xalkori (crizotinib) Pfizer Canada ULC Concluded with an LOI ROS1-positive advanced Non-Small Cell Lung Cancer
Ibrance/fulvestrant (palbociclib/fulvestrant) Pfizer Canada ULC Concluded with an LOI Advanced or Metastatic Breast Cancer
Imfinzi (durvalumab) AstraZeneca Canada Inc. Concluded with an LOI Non-small Cell Lung Cancer
Tafinlar/Mekinist (dabrafenib/trametinib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Melanoma adjuvant therapy
Trazimera (trastuzumab) Pfizer Canada ULC Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Herzuma (trastuzumab) Teva Canada Limited Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Ogivri (trastuzumab) BGP Pharma ULC Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Opsumit (macitentan) Actelion Pharmaceuticals Ltd. Concluded with an LOI Pulmonary Arterial Hypertension
Brilinta (ticagrelor) AstraZeneca Canada Inc. Concluded with an LOI secondary prevention of atherothrombotic events
Triamcinolone Hexacetonide (triamcinolone hexacetonide) Medexus Inc. Concluded with an LOI Rheumatoid Arthritis
Skyrizi (risankizumab) AbbVie Corporation Concluded with an LOI Plaque psoriasis
Vyzulta (latanoprostene bunod) Bausch Health, Canada Inc. Concluded with an LOI Open-angle Glaucoma
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Folotyn (pralatrexate) Servier Canada Inc. Concluded with an LOI Peripheral T-Cell Lymphoma
Botox (onabotulinumtoxin a) Allergan Inc. Concluded without agreement migraine, chronic
Xermelo (telotristat) Ipsen Biopharmaceuticals Negotiations were not pursued carcinoid syndorme
Jublia (efinaconazole) Bausch Health, Canada Inc. Negotiations were not pursued onychomycosis
Pifletro (doravirine) Merck Canada Inc. Concluded with an LOI HIV Infection
Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate) Merck Canada Inc. Concluded with an LOI HIV Infection
Cresemba (isavuconazole) AVIR Pharma Inc. Concluded with an LOI Treatment of invasive aspergillosis and mucormycosis
Unituxin (dinutuximab) United Therapeutics Concluded with an LOI neuroblastoma
Xtandi (enzalutamide) Astellas Pharma Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Melanoma adjuvant therapy
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Negotiations were not pursued Hodgkin's Lymphoma
Radicava (edaravone) Mitsubishi Tanabe Pharma Corporation Concluded with an LOI amyotrophic lateral sclerosis
Eucrisa (crisaborole) Pfizer Canada ULC Negotiations were not pursued Atopic dermatitis
Brineura (cerliponase alfa) BioMarin Pharmaceutical Inc. Concluded with an LOI neuronal ceroid lipofuscinosis type 2
Kalydeco (ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Zirabev (bevacizumab) Pfizer Canada ULC Concluded with an LOI Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Spinraza (nusinersen) Biogen Canada Inc. Concluded with an LOI Spinal Muscular Atrophy
Xeljanz (tofacitinib) Pfizer Canada ULC Concluded with an LOI Ulcerative Colitis
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Concluded with an LOI renal cell carcinoma
Mvasi (bevacizumab) Amgen Canada Inc. Concluded with an LOI Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Ella (ulipristal acetate) Allergan Inc. Concluded with an LOI prevention of pregnancy
Segluromet (ertugliflozin/metformin hydrochloride) Merck Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Steglatro (ertugliflozin) Merck Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Fulphila (pegfilgastrim) BGP Pharma ULC Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Xeljanz XR (tofacitinib) Pfizer Canada ULC Concluded with an LOI Rheumatoid Arthritis
Humira (citrate-free) (adalimumab citrate-free) AbbVie Corporation Concluded without agreement Multiple Indications
Ozempic (semaglutide) Novo Nordisk Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Herceptin SC (trastuzumab) Hoffmann-La Roche Concluded without agreement breast cancer
Tagrisso (osimertinib) AstraZeneca Canada Inc. Concluded with an LOI first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC)
Lenvima (lenvatinib) Eisai Limited Negotiations were not pursued advanced or metastatic, clear-cell renal cell carcinoma
Harvoni (ledipasvir/sofosbuvir) Gilead Sciences Canada Inc. Concluded with an LOI Chronic Hepatitis C
Velphoro (sucroferric oxyhydroxide) Vifor Fresenius Medical Care Renal Pharma Concluded with an LOI Hyperphosphatemia, end-stage renal disease
Soliqua (lixisenatide/insulin glargine) Sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Perjeta/Herceptin (pertuzumab/trastuzumab) Hoffmann-La Roche Negotiations were not pursued early breast cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Negotiations were not pursued For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Daklinza (daclatasvir) Bristol Myers Squibb Canada Inc. Concluded with an LOI Chronic Hepatitis C
Januvia (sitagliptin phosphate) Merck Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Yervoy/Opdivo (nivolumab/ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI renal cell carcinoma
Gazyva (obinutuzumab) Hoffmann-La Roche Negotiations were not pursued Follicular Lymphoma
Erleada (apalutamide) Janssen Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Xarelto (rivaroxaban) Bayer Inc. Concluded with an LOI Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.
Ozurdex (dexamethasone) Allergan Inc. Negotiations were not pursued Diabetic Macular Edema
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded with an LOI HIV infection
Fibristal (ulipristal acetate) Allergan Inc. Concluded with an LOI Intermittent treatment of moderate to severe signs and symptoms of uterine fibroids
uterine fibroids
Alecensaro (alectinib) Hoffmann-La Roche Concluded with an LOI Non-Small Cell Lung Cancer (First Line)
Praluent (alirocumab) Sanofi-aventis Canada Inc. Concluded without agreement Atherosclerotic cardiovascular disease
Orkambi (lumacaftor/ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Negotiations were not pursued Cystic Fibrosis, F508del CFTR mutation
Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate) Teva Canada Limited Concluded without agreement Asthma
Aermony Respiclick (fluticasone propionate) Teva Canada Limited Concluded without agreement Asthma
Viberzi (eluxadoline) Allergan Inc. Negotiations were not pursued Irritable Bowel Syndrome
Kanuma (sebelipase alfa) Alexion Pharma GMBH Concluded with an LOI Lysosomal acid lipase deficiency
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) GlaxoSmithKline Concluded with an LOI Chronic Obstructive Pulmonary Disease
Mavenclad (cladribine) EMD Serono a Division of EMD Inc. Canada Concluded with an LOI Relapsing-Remitting Multiple Sclerosis
Nucynta (tapentadol hydrochloride) Paladin Labs Inc. Negotiations were not pursued Pain, severe
Fasenra (benralizumab) AstraZeneca Canada Inc. Concluded with an LOI Eosinophilic Asthma
Dysport Therapeutic (abobotulinumtoxina) Ipsen Biopharmaceuticals Concluded with an LOI Lower Limb Spasticity
Nitisinone (nitisinone) Cycle Pharmaceuticals Ltd. Concluded with an LOI Hereditary Tyrosinemia Type 1
Taltz (ixekizumab) Eli Lilly Canada Inc. Concluded with an LOI Psoriatic Arthritis
Duodopa (levodopa/carbidopa) AbbVie Corporation Concluded with an LOI Parkinson's Disease
Probuphine (buprenorphine) Knight Therapeutics Concluded with an LOI Opioid Use Disorder
Ozanex (ozenoxacin) Ferrer Internacional Negotiations were not pursued Impetigo
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) Janssen Inc. Concluded without agreement HIV infection
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Concluded with an LOI Metastatic Colorectal Cancer
Besponsa (inotuzumab ozogamicin) Pfizer Canada ULC Concluded with an LOI Acute Lymphoblastic Leukemia
Tecentriq (atezolizumab) Hoffmann-La Roche Concluded with an LOI Non-small Cell Lung Cancer
Dupixent (dupilumab) Sanofi Genzyme Concluded with an LOI Atopic dermatitis
Lapelga (pegfilgrastrim) Apobiologix Concluded with an LOI Febrile Neutropenia
Siliq (brodalumab) Valeant Canada Concluded with an LOI Psoriasis, moderate to severe plaque
Prevymis (letermovir) Merck Canada Inc. Concluded with an LOI Cytomegalovirus infection prophylaxis
Juluca (dolutegravir/rilpivirine) ViiV Healthcare Concluded with an LOI HIV infection
Akynzeo (netupitant/palonosetron) Purdue Pharma Concluded with an LOI Nausea and vomiting (chemotherapy induced) prevention
Toujeo (insulin glargine injection) Sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Rituxan SC (rituximab) Hoffmann-La Roche Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Kevzara (sarilumab) Sanofi-aventis Canada Inc. Concluded with an LOI Rheumatoid Arthritis
Dysport Therapeutic (abobotulinumtoxina) Ipsen Biopharmaceuticals Concluded with an LOI Upper Limb Spasticity
Dysport Therapeutic (abobotulinumtoxina) Ipsen Biopharmaceuticals Concluded with an LOI Cervical dystonia
Enstilar (calcipotriol/betamethasone) LEO Pharma Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Classic Hodgkin's Lymphoma
Kisqali (ribociclib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Advanced or Metastatic Breast Cancer
Lartruvo (olaratumab) Eli Lilly Canada Inc. Concluded without agreement Advanced Soft Tissue Sarcoma
Stivarga (regorafenib) Bayer Inc. Concluded with an LOI Unresectable Hepatocellular Carcinoma
Alecensaro (alectinib) Hoffmann-La Roche Concluded with an LOI Locally advanced or metastatic non-small cell lung cancer
Vectibix (panitumumab) Amgen Canada Inc. Negotiations were not pursued Left Sided Metastatic Colorectal Cancer
Bavencio (avelumab) EMD Serono a Division of EMD Inc. Canada Concluded with an LOI Metastatic Merkel Cell Carcinoma
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Metastatic Urothelial Carcinoma
Venclexta (venetoclax) AbbVie Corporation Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Hodgkin's Lymphoma
Ocrevus (ocrelizumab) Hoffmann-La Roche Concluded with an LOI Primary Progressive Multiple Sclerosis
MDK-Nitisinone (nitisinone) MendeliKABS Inc Concluded with an LOI Hereditary Tyrosinemia Type 1
Monoprost (latanoprost) Laboratoires Thea Concluded without agreement Glaucoma and Ocular Hypertension
Actemra (tocilizumab) Hoffmann-La Roche Concluded with an LOI Giant Cell Arteritis
Vemlidy (tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded without agreement Hepatitis B
Ilaris (canakinumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Systemic juvenile idiopathic arthritis
Renflexis (infliximab) Merck Canada Inc. Concluded with an LOI Rheumatic Conditions
Izba (travoprost) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Open-angle Glaucoma
Rexulti (brexpiprazole) Otsuka Canada Pharmaceuticals Concluded with an LOI Schizophrenia
Galafold (migalastat) Amicus Therapeutics Concluded with an LOI Fabry's Disease
Fiasp (insulin aspart) Novo Nordisk Canada Inc. Concluded without agreement Diabetes Mellitus, Type 1 & 2
Pomalyst (pomalidomide) Celgene Inc. Concluded with an LOI Multiple Myeloma
Mictoryl Pediatric (propiverine hydrochloride) Duchesnay Inc. Concluded with an LOI Overactive bladder
Jevtana (cabazitaxel) Sanofi-aventis Canada Inc. Concluded with an LOI Castrate resistant metastatic prostate cancer
Rosiver (ivermectin) Galderma Canada Inc. Concluded without agreement Rosacea
Rydapt (midostaurin) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Acute Myeloid Leukemia
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Tagrisso (osimertinib) AstraZeneca Canada Inc. Concluded with an LOI Non-Squamous Non-Small Cell Lung Cancer
Gazyva (obinutuzumab) Hoffmann-La Roche Concluded with an LOI Follicular Lymphoma
Orfadin (nitisinone) Sobi Canada Inc. Concluded with an LOI Hereditary Tyrosinemia Type 1
Tremfya (guselkumab) Janssen Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Procysbi (cysteamine bitartrate) Horizon Therapeutics Ireland DAC Concluded with an LOI Nephropathic cystinosis
Maviret (glecaprevir/pibrentasvir) AbbVie Corporation Concluded with an LOI Chronic Hepatitis C
Movapo (apomorphine hydrochloride) Paladin Labs Inc. Concluded with an LOI Parkinson's Disease
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Gilead Sciences Canada Inc. Concluded with an LOI Chronic Hepatitis C
Spinraza (nusinersen) Biogen Canada Inc. Concluded with an LOI Spinal Muscular Atrophy
Zykadia (ceritinib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Non-Squamous Non-Small Cell Lung Cancer
Viacoram (perindopril arginine/amlodipine) Servier Canada Inc. Concluded without agreement Hypertension
Adlyxine (lixisenatide) Sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Repatha (evolocumab) Amgen Canada Inc. Concluded without agreement Primary hyperlipidemia and mixed dyslipidemia
Ocrevus (ocrelizumab) Hoffmann-La Roche Concluded with an LOI multiple sclerosis, relapsing
Tresiba (insulin degludec) Novo Nordisk Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Stivarga (regorafenib) Bayer Inc. Negotiations were not pursued Metastatic Colorectal Cancer
VPRIV (velaglucerase) Shire Pharma Canada ULC Concluded with an LOI Gaucher disease
Elelyso (taliglucerase alfa) Pfizer Canada ULC Concluded with an LOI Gaucher disease
Cerezyme (imiglucerase) Sanofi Genzyme Canada Concluded without agreement Gaucher disease
Kyleena (levonorgestrel) Bayer Inc. Concluded with an LOI Conception Control
Invega Trinza (paliperidone palmitate) Janssen Inc. Concluded with an LOI Schizophrenia
Strensiq (asfotase alfa) Alexion Pharma GMBH Concluded with an LOI pediatric-onset hypophosphatasia
Narcan (naloxone hydrochloride) Adapt Pharma Operations Limited Concluded with an LOI Opioid Overdose
Methadose (methadone hydrochloride) Mallinckrodt Canada ULC Concluded without agreement Opioid Dependence
Metoject (methotrexate) Medexus Inc. Concluded with an LOI Rheumatic Conditions
Copaxone (glatiramer acetate) Teva Canada Limited Concluded without agreement Clinically Isolated Syndrome
Botox (onabotulinumtoxin a) Allergan Inc. Concluded with an LOI Multiple Indications
Faslodex (fulvestrant) AstraZeneca Canada Inc. Concluded without agreement Locally Advanced or Metastatic Breast Cancer
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Classic Hodgkin's Lymphoma
Onivyde (irinotecan liposome) Shire Pharma Canada ULC Concluded without agreement Metastatic Pancreatic Cancer
Yervoy/Opdivo (nivolumab/ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Metastatic Melanoma
Glatect (glatiramer acetate) Pendopharm Concluded with an LOI Multiple Sclerosis, relapsing - remitting
Cerdelga (eliglustat) Sanofi Genzyme Canada Concluded without agreement Gaucher disease
Ocaliva (obeticholic acid) Intercept Pharma Canada Concluded with an LOI Primary biliary cholangitis
Caprelsa (vandetanib) Sanofi Genzyme Canada Concluded with an LOI Medullary Thyroid Cancer
Erelzi (etanercept) Sandoz Canada Inc. Concluded with an LOI Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis
Zinbryta (daclizumab beta) Biogen Canada Inc. Negotiations were not pursued Multiple Sclerosis, relapsing
Darzalex (daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma
Lixiana (edoxaban) Servier Canada Inc. Concluded with an LOI Venous thromboembolism, treatment and recurrence prevention
Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded with an LOI HIV infection
Lancora (ivabradine) Servier Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Fibristal (ulipristal acetate) Allergan Inc. Concluded without agreement Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery
Mictoryl (propiverine hydrochloride) Duchesnay Inc. Concluded without agreement Overactive bladder
Kevzara (sarilumab) Sanofi-aventis Canada Inc. Concluded without agreement Rheumatoid Arthritis
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Acute Lymphoblastic Leukemia
Actikerall (fluorouracil/salicylic acid) Cipher Concluded with an LOI Hyperkeratotic actinic keratosis
Stelara (ustekinumab) Janssen Inc. Concluded without agreement Crohn's disease
Lixiana (edoxaban) Servier Canada Inc. Concluded with an LOI Non-valvular atrial fibrillation, prevention of stroke and systemic embolism
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Pediatric Acute Lymphoblastic Leukemia (ALL)
Ravicti (glycerol phenylbutyrate) Horizon Therapeutics Ireland DAC Concluded with an LOI Urea cycle disorders
Hemangiol (propranolol oral solution) Pierre Fabre Concluded with an LOI Infantile hemangioma
Brivlera (brivaracetam) UCB Canada Inc. Concluded with an LOI Epilepsy, partial-onset seizures
Ibrance (palbociclib) Pfizer Canada ULC Concluded with an LOI Advanced Breast Cancer
Quinsair (levofloxacin) Raptor Pharmaceuticals Inc. Concluded with an LOI Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections
Rituxan (rituximab) Hoffmann-La Roche Negotiations were not pursued Acute Lymphoblastic Leukemia
Kyprolis (carfilzomib) Amgen Canada Inc. Concluded with an LOI Multiple Myeloma
Uptravi (selexipag) Actelion Pharmaceuticals Ltd. Concluded with an LOI Pulmonary Arterial Hypertension
Synjardy (empagliflozin/metformin) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Diabetes Mellitus, Type 2
Taltz (ixekizumab) Eli Lilly Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Kuvan (sapropterin dihydrochloride) BioMarin Pharmaceutical Inc. Concluded with an LOI Phenylketonuria
Jardiance (empagliflozin) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Diabetes Mellitus, Type 2 with high cardiovascular risk
Invokamet (canagliflozin/metformin hydrochloride) Janssen Inc. Concluded without agreement Diabetes Mellitus, Type 2
Brilinta (ticagrelor) AstraZeneca Canada Inc. Concluded without agreement Prevention of atherothrombotic events with history of myocardial infarction
Descovy (emtricitabine/tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded without agreement HIV infection
Cosentyx (secukinumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Ankylosing spondylitis
Cosentyx (secukinumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Psoriatic Arthritis
Revestive (teduglutide) Shire Pharma Canada ULC Concluded with an LOI Short Bowel Syndrome (SBS)
Praluent (alirocumab) Sanofi-aventis Canada Inc. Concluded with an LOI Primary hypercholesterolemia (non-familial and heterozygous familial)
Kyprolis (carfilzomib) Amgen Canada Inc. Concluded with an LOI Multiple Myeloma
Trulicity (dulaglutide) Eli Lilly Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Nucala (mepolizumab) GlaxoSmithKline Concluded with an LOI Severe Eosinophilic Asthma
Vimizim (elosulfase alfa) BioMarin Pharmaceutical Inc. Concluded with an LOI Mucopolysaccharidosis IVA (Morquio A syndrome)
Xolair (omalizumab) Novartis Pharmaceuticals Canada Inc. Concluded without agreement Severe Persistent Asthma
Fycompa (perampanel) Eisai Limited Concluded with an LOI Epilepsy, primary generalized tonic-clonic seizures
Pheburane (sodium phenylbutyrate) Médunik Concluded with an LOI Urea cycle disorders
Naglazyme (galsulfase) BioMarin Pharmaceutical Inc. Negotiations were not pursued Mucopolysaccharidosis VI
Repatha (evolocumab) Amgen Canada Inc. Concluded with an LOI Primary hyperlipidemia and mixed dyslipidemia
Prolia (denosumab) Amgen Canada Inc. Concluded with an LOI Osteoporosis in Men
Kalydeco (ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded without agreement Cystic Fibrosis (CFTR gating mutations)
Truvada (emtricitabine/tenofovir disoproxil fumarate) Gilead Sciences Canada Inc. Negotiations were not pursued HIV infection, pre-exposure prophylaxis
Strensiq (asfotase alfa) Alexion Pharma GMBH Concluded without agreement pediatric-onset hypophosphatasia
Tafinlar/Mekinist (dabrafenib/trametinib) Novartis Pharmaceuticals Canada Inc. Negotiations were not pursued Non-Small Cell Lung Cancer (with CNS metastases)
Giotrif (afatinib) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Advanced Non Small Cell Lung Cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Squamos Cell Carcinoma of the Head and Neck
Simponi IV (golimumab) Janssen Inc. Concluded without agreement Rheumatoid Arthritis
Stivarga (regorafenib) Bayer Inc. Concluded with an LOI Gastrointestinal Stromal Tumours
Basaglar (insulin glargine) Eli Lilly Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Mifegymiso (mifepristone and misoprostol) Celopharma Concluded with an LOI Medical termination of pregnancy
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Non-small Cell Lung Cancer
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Non-small Cell Lung Cancer
Neupro (rotigotine) UCB Canada Inc. Concluded with an LOI Parkinson's Disease
Brenzys (etanercept) Merck Canada Inc. Concluded with an LOI Rheumatoid Arthritis and Ankylosing Spondylitis
Afinitor (everolimus) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Neuroendocrine tumours of Gastrointestinal or Lung origin
XigDuo (dapagliflozin/metformin hydrochloride) AstraZeneca Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Humira (adalimumab) AbbVie Corporation Concluded with an LOI Ulcerative Colitis
Avastin (bevacizumab) Hoffmann-La Roche Concluded with an LOI Platinum-Resistant Ovarian Cancer
Avastin (bevacizumab) Hoffmann-La Roche Concluded with an LOI Metastatic Colorectal Cancer
Sublinox (zolpidem tartrate) Valeant Canada Negotiations were not pursued Insomnia, short-term treatment
Ninlaro (ixazomib) Takeda Canada Inc. Negotiations were not pursued Multiple Myeloma
Eylea (aflibercept) Bayer Inc. Concluded with an LOI Macular edema secondary to branch retinal vein occlusion
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded with an LOI HIV infection
Entresto (sacubitril/valsartan) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Entyvio (vedolizumab) Takeda Canada Inc. Concluded with an LOI Crohn's disease
Entyvio (vedolizumab) Takeda Canada Inc. Concluded with an LOI Ulcerative Colitis
Epclusa (sofosbuvir/velpatasvir) Gilead Sciences Canada Inc. Concluded with an LOI Chronic Hepatitis C
Sunvepra (asunaprevir) Bristol Myers Squibb Canada Inc. Concluded with an LOI Chronic Hepatitis C
Zepatier (elbasvir/grazoprevir) Merck Canada Inc. Concluded with an LOI Chronic Hepatitis C
Otezla (apremilast) Celgene Inc. Concluded without agreement Psoriatic Arthritis
Plegridy (peginterferon beta-1a) Biogen Canada Inc. Concluded with an LOI Multiple Sclerosis, relapsing
Opsumit (macitentan) Actelion Pharmaceuticals Ltd. Concluded without agreement Pulmonary Arterial Hypertension
Caprelsa (vandetanib) Sanofi Genzyme Canada Concluded without agreement Medullary Thyroid Cancer
Jakavi (ruxolintib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Polycythemia vera
Alecensaro (alectinib) Hoffmann-La Roche Negotiations were not pursued Non-Small Cell Lung Cancer (with CNS metastases)
Stelara (ustekinumab) Janssen Inc. Negotiations were not pursued Psoriatic Arthritis
Votrient (pazopanib hydrochloride) GlaxoSmithKline Concluded with an LOI Metastatic Renal Cell Carcinoma
Signifor (pasireotide diaspartate) Novartis Pharmaceuticals Canada Inc. Negotiations were not pursued Cushing's disease
Samsca (tolvaptan) Otsuka Canada Pharmaceuticals Negotiations were not pursued Hyponatremia, non-hypovolemic
Imbruvica (ibrutinib) Janssen Inc. Concluded with an LOI Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Grastofil (filgrastim) ApoPharm Inc. Concluded with an LOI Prevention or treatment of neutropenia in various indications
Xolair (omalizumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Chronic Idiopathic Urticaria
Imbruvica (ibrutinib) Janssen Inc. Concluded with an LOI Mantle Cell Lymphoma
Lenvima (lenvatinib) Eisai Limited Concluded with an LOI Differentiated Thyroid Cancer
Mozobil (plerixafor) Sanofi-aventis Canada Inc. Concluded with an LOI Non-Hodgkin's Lymphoma and Multiple Myeloma
Rituxan SC (rituximab) Hoffmann-La Roche Concluded with an LOI ALL for ritux sub-cu
Otezla (apremilast) Celgene Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Forxiga (dapagliflozin) AstraZeneca Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Vectibix (panitumumab) Amgen Canada Inc. Concluded with an LOI Metastatic Colorectal Cancer
Cotellic (cobimetinib) Hoffmann-La Roche Concluded with an LOI Metastatic Melanoma
Esbriet (pirfenidone) Hoffmann-La Roche Concluded with an LOI Pulmonary fibrosis (idiopathic, mild to moderate)
Ferriprox (deferiprone) ApoPharm Inc. Concluded with an LOI Transfusional iron overload
Ofev (nintedanib) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Idiopathic pulmonary fibrosis (IPF)
Simponi SC (golimumab) Janssen Inc. Concluded with an LOI Ulcerative Colitis
Arnuity Ellipta (fluticasone furoate) GlaxoSmithKline Concluded with an LOI Asthma
Breo Ellipta (fluticasone furoate/vilanterol) GlaxoSmithKline Concluded with an LOI Asthma
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Metastatic Renal Cell Carcinoma
Cosentyx (secukinumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Non-small Cell Lung Cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Metastatic Melanoma
Lemtrada (alemtuzumab) Sanofi Genzyme Canada Concluded with an LOI Relapsing-Remitting Multiple Sclerosis
Xeljanz (tofacitinib) Pfizer Canada ULC Concluded with an LOI Rheumatoid Arthritis
Daklinza (daclatasvir) Bristol Myers Squibb Canada Inc. Concluded without agreement Chronic Hepatitis C
Zydelig (idelalisib) Gilead Sciences Canada Inc. Negotiations were not pursued Follicular Lymphoma
Jardiance (empagliflozin) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Diabetes Mellitus, Type 2 with high cardiovascular risk
Trajenta/Jentaduo (linagliptin (linagliptin/metformin)) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Diabetes Mellitus, Type 2
Nesina (alogliptin) Takeda Canada Inc. Negotiations were not pursued Diabetes Mellitus, Type 2
Prezcobix (darunavir/cobicistat) Janssen Inc. Concluded with an LOI HIV Infection
Inspiolto Respimat (tiotropium/olodaterol) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Heart failure, NYHA class II
Spiriva Respimat (tiotropium bromide) Boehringer Ingelheim (Canada) Ltd. Ltee. Concluded with an LOI Chronic Obstructive Pulmonary Disease
Byetta (exenatide) AstraZeneca Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Acute Lymphoblastic Leukemia
Januvia (sitagliptin phosphate) Merck Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Janumet (sitagliptin phosphate) Merck Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Kazano (alogliptin/metformin) Takeda Canada Inc. Negotiations were not pursued Diabetes Mellitus, Type 2
Cimzia (certolizumab pegol) UCB Canada Inc. Concluded with an LOI Ankylosing spondylitis
Butrans (buprenorphine) Purdue Pharma Concluded without agreement Pain, persistent (moderate intensity)
Actemra SC (tocilizumab) Hoffmann-La Roche Concluded with an LOI Rheumatoid Arthritis
Incruse Ellipta (umeclidinium) GlaxoSmithKline Concluded with an LOI Chronic Obstructive Pulmonary Disease
Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate) AstraZeneca Canada Inc. Concluded with an LOI Chronic Obstructive Pulmonary Disease
Inflectra (infliximab) Hospira Healthcare Corporation Concluded with an LOI Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis
Jinarc (tolvaptan) Otsuka Canada Pharmaceuticals Negotiations were not pursued Autosomal dominant polycystic kidney disease (ADPKD)
Imbruvica (ibrutinib) Janssen Inc. Negotiations were not pursued Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Darzalex (daratumumab) Janssen Inc. Negotiations were not pursued Multiple Myeloma
Intuniv XR (guanfacine hydrochloride) Shire Pharma Canada ULC Negotiations were not pursued Attention-deficit/hyperactivity disorder (ADHD)
Aptiom (eslicarbazepine acetate) Sunovion Pharmaceuticals Canada Inc. Concluded with an LOI Epilepsy, partial-onset seizures
Simbrinza (brinzolamide/brimonidine) Alcon Concluded with an LOI Glaucoma and Ocular Hypertension